Dividend to be Paid Consistent with the Company's Cash Dividend Policy Dividend to be Paid Consisten

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KM

The consensus price target hints at a 79.1% upside potential for Kamada (KMDA). While empirical rese

Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the qua

Kamada (KMDA) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estim

Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000

Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.16 per share which beat the analyst consensus

REHOVOT, Israel and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE

REHOVOT, Israel, and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TAS

REHOVOT, Israel, and HOBOKEN, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.

Kamada (NASDAQ: KMDA - Get Free Report) and InflaRx (NASDAQ: IFRX - Get Free Report) are both small-

Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of m

REHOVOT, Israel and HOBOKEN, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.

Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of m

Findings from analyses of CMV high-risk lung transplant recipients suggest CYTOGAM use is associated

Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of m

REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE

Kamada NASDAQ: KMDA reiterated its full-year 2026 outlook after reporting first-quarter results that

Kamada Ltd. (KMDA) Q1 2026 Earnings Call Transcript

Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the qua

Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000

Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.07 per share which missed the analyst consens

Q1-2026 Revenue of $45.2 Million, up 3% Year-over-Year; Adjusted EBITDA of $11.6 Million, representi

Get a deeper insight into the potential performance of Kamada (KMDA) for the quarter ended March 202

REHOVOT, Israel and HOBOKEN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.

Kamada Ltd. (the "Company") (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical compa

San Antonio Center Cleared to Commence Commercial Sales of Normal Source PlasmaState of the Art Faci

Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000

Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.06 per share which missed the analyst consens

Kamada (NASDAQ:KMDA) affirms FY2025 sales outlook from $178.000 million-$182.000 million to $178.000

HC Wainwright & Co. analyst Andrew S. Fein maintains Kamada (NASDAQ:KMDA) with a Buy and rais

Kamada ends its Phase 3 inhaled AAT trial after a futility analysis but maintains 2025 guidance and

Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Dem

Kamada (NASDAQ:KMDA) affirms FY2025 sales outlook from $178.000 million-$182.000 million to $178.000

Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.09 per share which missed the analyst consens

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its

Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company